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Background: Activated vitamin D is the mainstay of treatment for secondary hyperparathyroidism (SHPT) in chronic
hemodialysis patients. However, the optimal route of administration is still debated. The aim of our study was to
compare efficacy of oral vs intravenous (IV) administration of alfacalcidol in hemodialysis. A secondary objective was
to determine the cost-effectiveness advantage of oral administration.
Methods: Eighty-eight chronic hemodialysis patients receiving IV alfacalcidol three times a week were included in
the study. All were switched to the same dose of alfacalcidol given orally three times a week during the
hemodialysis session. A budget impact analysis was performed.
Results: Mean patient age was 64 years old and 43% were males. The mean alfacalcidol dose administered was
2.1 μg three times a week. After three months, serum parathormone (PTH) levels decreased from 80 to 59 pmol/L
(p = 0.001) and total serum calcium levels increased from 2.34 to 2.40 mmol/L (p = 0.002). After six months, total
serum calcium levels were still significantly higher. Alfacalcidol dosage was significantly decreased during study
period; the mean reduction was 0.44 μg per dose. Finally, oral administration was associated with an annual cost
reduction of 197 678$CAN and an annual nursing time reduction of 25 days.
Conclusion: Our findings support that switching IV to oral administration of alfacalcidol during hemodialysis
sessions may lead to a similar control of SHPT with lower doses of activated vitamin D. This is a good strategy for
optimizing compliance and may allow a dose reduction because of a greater efficacy to suppress PTH. Oral
administration also has significant cost-effectiveness advantages.
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Secondary hyperparathyroidism is an early and common
complication of chronic kidney disease (CKD). This
phenomenon is caused by several factors, such as calci-
triol deficiency, progressive hyperphosphatemia, relative
hypocalcemia and parathormone (PTH) skeletal resist-
ance [1]. Prevalence of native vitamin D deficiency ex-
ceeds 80% in advanced CKD population [2]. We know
that vitamin D plays a central role in phosphocalcic and
bone metabolism in the general and the CKD popula-
tion. However, 25-vitamine D needs to undergo 1-α-
hydroxylation before being active. Because kidneys are
the primary site for this hydroxylation, active 1,25-* Correspondence: mvallee.hmr@ssss.gouv.qc.ca
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reproduction in any medium, provided the orvitamin D or calcitriol is consequently deficient in CKD
and also contribute to PTH elevation [2]. Down regula-
tion of vitamin D receptor (VDR) and decreased cal-
cium sensing receptor (CaSR) on parathyroid cells have
also been implicated in secondary HPT pathogenesis
[3,4]. Such changes alter bone remodelling, may exacer-
bate osteoporosis and even lead to osteitis fibrosa, a pat-
tern of renal osteodystrophy. Chronic excessive PTH
levels are frequent in end-stage renal disease (ESRD)
and are associated with parathyroid hyperplasia and
eventually autonomous secretion. The first intervention
to tackle this problem is to keep serum phosphorus
level close to the normal range with diet, good dialysis
and phosphate binders (PB). Once serum phosphorus is
controlled, administration of activated vitamin D is the
mainstay of treatment of SHPT in chronic hemodialysisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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vitamin D analogs regulate PTH. Vitamin D analogs in-
crease serum calcium levels by enhancing intestinal cal-
cium absorption resulting in a decrease in PTH levels [5].
These analogs also produce a direct inhibition of PTH
gene transcription in parathyroid cells [5]. Finally, acti-
vated vitamin D could also move the set point for calcium
in parathyroid glands to the left side, which means that
PTH secretion is reduced in response to serum calcium
levels. Activated vitamin D can be administered orally,
daily or intermittently and intravenously (IV three times a
week during HD sessions).
Studies comparing oral and IV routes of administration
for active vitamin D have found conflicting results [6-13].
The optimal route of administration for activated vitamin
D is still debated [13] because there are limited random-
ized placebo-controlled studies that directly compare
pulse-oral to pulse-IV activated vitamin D administration
for the treatment of SHPT in ESRD.
In our HD center, IV administration is mostly used for
compliance concerns in patients with uncontrolled SHPT
with daily oral regimen. Moreover, alfacalcidol is preferred
to calcitriol because of a lower cost. Calcitriol is thus re-
served for patients with hepatic dysfunction, hypoparathyr-
oidism following parathyroidectomy or refractory SHPT.
Most previous clinical studies comparing routes of admin-
istration of activated vitamin D in HD population were
conducted with calcitriol and only a few studies considered
alfacalcidol administration [11,14,15].
The primary objective of our study was to compare effi-
cacy and side effects of oral versus IV in-center adminis-
tration of alfacalcidol in HD. A secondary objective was to
evaluate the cost-effectiveness of oral compared to IV regi-
men. Our hypothesis was that intermittent oral adminis-
tration of alfacalcidol during HD sessions could be at least
as effective as IV administration for SHPT control in
regards to KDIGO guidelines [16]. Moreover, IV switch to




We performed a retrospective observational study among
subjects on chronic HD treatment for at least six months at
Maisonneuve-Rosemont Hospital. All subjects treated with
the same dose of alfacalcidol given IV three times a week
for the last three months were included. We excluded pa-
tients with intestinal malabsorption or hepatic disease.
Assessment of outcome
Oral alfacalcidol was started at the same dose as prior
IV dose and administered by nursing staff at the end of
each HD treatment. Alfacalcidol dose was then adjusted
according to KDIGO recommendations [16].Collected demographic data for each patient included:
age, sex, ESRD etiology, HD vintage and history of para-
thyroidectomy. Monthly biochemical parameters were
collected for three months before and up to six months
after the switch from IV to oral thrice-weekly alfacalcidol.
Biochemical and pharmacological data included: serum
calcium, phosphorus, albumin, bicarbonates, magnesium,
intact PTH, 25(OH)D3, 1.25(OH)2D3, alkaline phosphat-
ase, phosphocalcic product, calcium concentration dialysis
bath, dose of phosphate binders (calcium carbonate, seve-
lamer hydrochloride, lanthanum carbonate, aluminium/
magnesium based binders), dose of cinacalcet as well as
alfacalcidol.
Pharmaco-economic analysis
Annual costs and nursing time were calculated for both
oral and IV routes of administration. Ten patients were
identified for the evaluation of the time and motion study
required for drug administration. Annual costs included
drug price, medical supplies and nursing time and were ex-
trapolated for the six-month study and nursing time evalu-
ation. Cost for nursing time were calculated by multiplying
nursing time by average hourly wage for nephrology nurses
in Quebec, including social benefits, obtained from the
Quebec Ministry of Health [17].
Statistical analysis
Parameters at baseline, 3 and 6 months after the switch
were compared using a Student’s paired t-test.
Ethical considerations
The Research and Ethics Committee of Maisonneuve-
Rosemont Hospital approved the study.
Results
Patient characteristics
The cohort consisted of 88 patients with a mean age of
64 ± 14 years; 43% were males. They represented 24% of
the entire HD cohort. The mean IV alfacalcidol dose
was 2,10 ± 0.86 μg three times a week at study entry and
before the switch to oral alfacalcidol. Baseline charac-
teristics, including ESRD etiologies and initial serum
biochemistry results are summarized in Table 1. No pa-
tients died or were lost to follow-up during the study.
Effects on serum biochemistry and drug
dosage adjustments
Three months after switching from IV to oral alfacalci-
dol, total serum calcium levels increased from 2.34 to
2.40 mmol/L (p = 0.002), whereas serum PTH levels sig-
nificantly decreased from 80 to 59 pmol/L (p < 0.001)
and serum phosphorus levels did not change signifi-
cantly (Table 2). There was a small decrease of alfacalci-
dol dosage from baseline to three months (p = 0.04).
Table 1 Characteristics of patients at baseline
(N = 88 patients)
Characteristics Mean or percentage
Age (year), mean (SD) 64 (14)
Sex (male), n (%) 38 (43.2)
IV dosage of alfacalcidol, mean (SD) 2.1 μg 3 times a week (0.86)
ESRD etiology, n (%)
Diabetic nephropathy 30 (34)
Hypertensive nephropathy 30 (34)
Glomerular disease 15 (17)
Others 13 (15)
Cinacalcet use, n (%) 30 (34)
Phosphate binders use, n (%)
Calcium based 64 (72)
Sevelamer 50 (57)
Lanthanum 9 (10)
No phosphate binder 8 (9)
25 vitamin D use, n (%) 0 (0)
Data are presented as number (percentage) or mean (standard deviation),
SD: standard deviation.
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alfacalcidol dosage became statistically significant com-
pared to baseline (p < 0.001). There had been a 21% re-
duction of dosage, which corresponded to a mean
reduction of 0.54 μg per dose three times a week. At six
months, the increase in total serum calcium was still
significant (p < 0.001) but no episodes of hypercalcemia
were reported. However, serum PTH and phosphorus
levels were not significantly different from baseline values.
Concomitantly, serum 25(OH)D3 levels was clinically un-
changed, although statistically reduced (p < 0.001) while
1.25(OH)2D3 levels significantly increased from 32 at base-
line to 40 pmol/L at six months (p = 0.007). Moreover,
total alkaline phosphatase level significantly decreasedTable 2 Biochemical parameters and alfacalcidol dose at base
to oral administration
Serum parameters Baseline IV alfacalcidol
administration
Calcium, mmol/L (SD) 2.34 (0.17)
Phosphorus, mmol/L (SD) 1.49 (0.44)
Ca x PO4 (SD) 3.49 (1.06)
Intact PTH, pmol/L (SD) 79.7 (59)
Alkaline phosphatise (SD) 142.3 (103)
25(OH)D3, nmol/L (SD) 55 (20)
1,25(OH) 2D3 (pmol/L) (SD) 32 (19)
Mean alfacalcidol dose (SD) 2.1 μg 3 times a week (0.86)
Ca x PO4, Phosphocalcic product, SD, Standard deviation.
*P < 0.05 compared to baseline.
**P < 0.001 compared to baseline.three months after the switch; this reduction was still sig-
nificant at six months when compared to baseline levels.
There was no significant change in the cinacalcet dosage
of the 30 patients under this medication during the study
period. There was no significant change in phosphate
binders dose; although six patients had a slight increase,
eight patients had a small decrease in their phosphate
binder dose and eight patients did not take phosphate
binder during the study period. There was no change in
dialysate calcium concentration during the study period
that remains at 1.25 mmol/L for all patients.
Pharmaco-economic analysis
As shown in Table 3, annual costs related to nursing time
and medical supplies were much lower with oral alfacalci-
dol regimen. The annual cost reduction was 7270$CAN
for the entire cohort or 82.61$CAN per patient. More im-
portantly, there was a ten-fold decrease in annual drug
cost per patient, from 2493$CAN for IV alfacalcidol to
329$CAN for oral alfacalcidol. Thus, in our unit, com-
pared to IV, oral administration was associated with a total
annual cost reduction of 197 678$CAN (2246$CAD per
patient) and an annual nursing time reduction of 25 days.
Discussion
The primary objective of our study was to demonstrate
that oral intermittent administration of alfacalcidol in HD
was at least as effective as IV administration in controlling
PTH. Our results demonstrated that thrice-weekly oral
alfacalcidol administration is more effective than an
equivalent thrice-weekly IV regimen. We also found that
oral administration of alfacalcidol was associated with a
significant increase of serum calcium levels, a lower serum
PTH and total alkaline phosphatase levels. Reduction of
serum PTH and total alkaline phosphatase are usually pre-
dictive of better bone remodelling control in SHPT [18].
Such an apparent increased efficacy was associated with aline, at three months and at six months after the switch
3 months after switch
to oral alfacalcidol
6 months after switch
to oral alfacalcidol
2.40 (0.18)** 2.43 (0.17)**
1.58 (0.44) 1.57 (0.50)
3.78 (1.07)* 3.77 (1.18)
58.5 (56)** 78.2 (77)
127.7 (96)* 130.2 (103)*
57 (24) 50 (21)**
38 (17)* 40 (18)*
1.87 μg 3 times a week (0.92)* 1.56 μg 3 times a week (0.79)**
Table 3 Estimated annual costs per patient according to
alfacalcidol administration regimen
Cost per patient CAD$
IV administration Oral administration
Medical supplies 31.20 0
Nursing time 64.20 12.80
Drug 2492.80 329.20
Total 2588.20 342.00
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study period compared to prior IV dose. To our know-
ledge, this is the first study to show such findings. No epi-
sode of hypercalcemia was reported during the study
period, although this remains a long-term possibility if
alfacalcidol dosage is not carefully adjusted.
Several studies have shown that alfacalcidol is effective
for SHPT control when compared to others forms of ac-
tivated vitamin D [19-22]. Mitwalli et al. [14] reported in
2000 that oral intermittent administration of alfacalcidol
was at least as effective as IV administration in control-
ling serum PTH. Although all patients were initiated on
alfacalcidol 1 mcg three times per week, the final doses
within the oral and IV groups were not reported by the
authors. Some studies propose that pulse alfacalcidol
oral therapy is as effective as daily oral administration in
regards to PTH suppressive effect [11,15].
Some studies suggest that intermittent administration
is associated with a lower incidence of hypercalcemia
and may suppress PTH with more efficacy than daily ad-
ministration of activated vitamin D [23,24]. One study
showed that IV intermittent calcitriol therapy is the best
route of administration in regards to PTH suppressive
effect [6]. Another study also suggested that IV calcitriol
administration in the early stage of kidney failure can
prevent the exacerbation of parathyroid hyperplasia and
delay the apparition of nodular hyperplasia [4]. Others
demonstrated that IV calcitriol treatment has a superior
effect on bone remodelling [7,8]. However, more recent
publications have shown that high-dose intermittent oral
administration may be as effective as IV administration
in treating SHPT [1,9-11]. Zhou et al. published in 2009
a meta-analysis of randomized controlled trials compar-
ing intermittent IV and oral calcitriol in chronic HD
patients [12]. Six studies were considered for their meta-
analysis and they showed that there were no significant
differences between the two routes of administration in
regards to efficacy and adverse effects (hypercalcemia and/
or hyperphosphatemia).
The response to activated vitamin D therapy may also
be related to SHPT severity instead of the route of admin-
istration of calcitriol [9,25-27]. Obviously, activated vita-
min D efficacy is also linked to patient’s compliance with
the drug regimen [28]. Nonetheless, the optimal route ofadministration of activated vitamin D is still debated [13]
because there are limited randomized placebo-controlled
studies that directly compare pulse-oral to pulse-IV acti-
vated vitamin D administration for the treatment of SHPT
in ESRD.
Although it has not been demonstrated, we could
postulate that oral alfacalcidol higher efficacy is partially
related to the “first hepatic pass effect”. For example, we
can compare this phenomenon to Amiodarone class III
antiarrhythmic action which is mostly related to the
pharmacologic action of the hepatic metabolite [29,30].
Similarly, Alfacalcidol is a pro-drug that must undergo
hepatic 25-hydroxylation before being active [5]. This
hydroxylation may be greater when alfacalcidol is ad-
ministered orally avoiding rapid peripheral catabolism.
This phenomenon could lead to higher levels of 1.25
(OH)2D3, higher intestinal calcium absorption, slightly
higher levels of serum calcium and better control of
SHPT. However, efficacy could be different for a vitamin
D analog that would not be a pro-drug with hepatic
metabolism. For sure, we cannot exclude some tubing
adsorption with IV administration. Another potential
explanation comes from the fact that IV administration
of alfacalcidol yields a peak serum of medication that is
faster and higher than the oral administration of alfacal-
cidol. Thus, it is possible that this phenomenon in-
creases the catabolism of alfacalcidol and 1.25(OH)2D3.
Our secondary objective was to study the cost-
effectiveness of oral compared to IV alfacalcidol admin-
istration in HD. Oral administration is significantly
cheaper, which is consistent with literature [31]. It is
well known that SHPT in CKD patients has a significant
economic burden and must soon be recognized and
treated [31]. Savings are mainly related to lower drug
price and reduced nursing time, which is a major issue
in a context of nursing shortage.
Since our study is not a randomized control trial, we
cannot exclude that the observed results are due to un-
measured or unknown factors, other than the route of
alfacalcidol administration.
Conclusions
Although some studies have suggested that intermittent
IV administration of activated vitamin D analogs may be
associated with a better control of SHPT, it is not the
case for alfacalcidol, a pro-drug that needs hepatic hy-
droxylation before being active. Moreover, our findings
suggest that intermittent oral administration is even
more effective than equivalent IV dosage in regards to
PTH suppressive effect. For maintaining serum PTH
levels within target limits or for compliance purposes,
intermittent oral administration of alfacalcidol in an
HD unit is a much more cost-effective strategy. In our
unit, for 88 patients for whom intermittent activated
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propriate, such a strategy represents an annual saving of
197 678$CAN and significantly reduces nursing time
required for drug administration during HD sessions.
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